Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Maze Therapeutics is a precision medicine biotechnology company focused on developing therapies for genetically defined diseases by leveraging human genetic insights. The company uses its Compass platform to identify genetic modifiers that protect against disease, translating these findings into novel therapeutic candidates across multiple disease areas including cardiovascular, neurological, and metabolic disorders. With minimal revenue ($0.2B TTM) but positive operating margins (34.4%), MAZE appears to be generating income from collaboration agreements or milestone payments while advancing its clinical pipeline.
Maze monetizes its Compass genetic discovery platform through strategic partnerships with larger pharmaceutical companies, receiving upfront payments, research funding, and milestone payments as programs advance. The company's competitive advantage lies in its ability to identify protective genetic modifiers that can be translated into drug targets with validated human genetic evidence, reducing clinical development risk. The 100% gross margin reflects the service/IP-based revenue model with minimal COGS. Long-term value creation depends on advancing proprietary programs through clinical development and eventual commercialization or out-licensing.
Clinical trial data readouts and regulatory milestones for lead programs in cardiovascular and neurological indications
New strategic partnerships or expansion of existing collaborations with major pharmaceutical companies
Genetic target validation announcements from Compass platform identifying novel disease modifiers
FDA regulatory decisions including IND clearances and breakthrough therapy designations
Biotech sector M&A activity and valuation multiples for precision medicine companies
Clinical trial failure risk inherent to drug development, particularly for novel genetic modifier-based mechanisms without prior clinical validation
Regulatory pathway uncertainty for precision medicine approaches requiring companion diagnostics or genetic screening
Increasing competition in genetic medicine space from well-funded players including Vertex, Regeneron, and emerging gene therapy companies
Reimbursement challenges for genetically targeted therapies in cost-conscious healthcare environment
Large pharmaceutical companies developing internal genetic medicine capabilities, potentially reducing partnership demand
Academic institutions and other biotechs identifying similar protective genetic modifiers, creating target competition
Platform technology risk if competitors develop superior genetic discovery methods or AI-driven target identification
Despite current positive cash flow, future capital needs for advancing multiple clinical programs may require dilutive equity raises
Collaboration revenue concentration risk if dependent on small number of partnerships for operating cash flow
Negative ROE (-44.6%) and ROA (-29.9%) indicate accumulated losses despite recent profitability, suggesting historical cash burn
low - Pre-revenue biotech companies are largely insulated from GDP fluctuations as their value derives from clinical pipeline potential rather than current economic activity. However, broader risk appetite and venture capital availability can be affected by economic conditions, impacting ability to raise capital and sector valuations.
Rising interest rates negatively impact biotech valuations through two mechanisms: (1) higher discount rates reduce NPV of distant future cash flows from pipeline assets, and (2) increased competition from risk-free rates makes speculative biotech investments less attractive. The company's strong current ratio (17.70) and positive operating cash flow ($0.1B) provide some insulation from financing pressures, but equity valuation multiples compress in rising rate environments.
minimal - With debt/equity of only 0.06 and positive free cash flow, MAZE has negligible debt financing needs. Credit market conditions primarily affect the company through impact on partnership economics if pharma partners face financing constraints, and through broader biotech sector funding availability for future capital raises.
growth - Attracts speculative biotech investors focused on clinical pipeline optionality and platform technology value rather than current earnings. The 266.6% one-year return and 251.2% six-month return indicate momentum-driven trading, while the $2.3B market cap on $0.2B revenue (11.5x P/S) reflects growth expectations. High volatility profile typical of clinical-stage biotech with binary event risk around trial readouts.
high - Clinical-stage biotechnology stocks exhibit extreme volatility driven by binary clinical trial outcomes, regulatory decisions, and sector rotation. Recent 266.6% annual return demonstrates momentum characteristics. Stock likely experiences 40-60% intraday swings around data releases and trades with beta significantly above 1.0 relative to broader market.
